Antibody Engineering and Therapeutics
نویسندگان
چکیده
note: The views expressed herein are those of the authors and do not necessarily reflect the views of their respective employers. Speakers who wrote a summary of their own presentation are listed in the header for the relevant session. The majority of the other summaries in this report were based on PDFs of the presentations provided by speakers or on post-meeting input from the speakers. The authors thank all speakers who contributed to the report. When speakers could not contribute either the PDF or input, detailed summaries of their presentations were not prepared, although the names, affiliations and topics of all speakers were included in the report.
منابع مشابه
IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society
The 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics international conferences, and the 2010 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5-9, 2010 in San Diego, CA. The conferences were organized with a focus on antibody engineering only on the firs...
متن کاملIBC’s 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society
The 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences, and the 2012 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 3-6, 2012 in San Diego, CA. The meeting drew over 800 participants who attended sessions on a wide variety of topi...
متن کاملBispecific Antibodies: Bright Way for Cancer Therapeutics
Antibody based cancer therapeutics show great beneficial to more and more patients and the antibody drug market is growing fast. As Removab® approved in 2009 and BlincytoTM approved in 2014, bispecific antibodies with combination of two antigen binding specificities shed new light on antibody based cancer therapeutics especially when new technologies for engineering and manufacturing are availa...
متن کاملAntibody engineering & therapeutics, the annual meeting of the antibody society December 7–10, 2015, San Diego, CA, USA
The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society united over 800 participants from all over the world in San Diego from 6-10 December 2015. The latest innovations and advances in antibody research and development were discussed, covering a myriad of antibody-related topics by more than 100 speakers, who were carefully selected by The Antibody Soci...
متن کاملAntibody Therapeutics: Bench to Bedside.
Monoclonal antibodies have been considered promising therapeutic entities due to their highly specific binding to antigens. For oncology in particular, the tumor specific binding of an antibody, without affecting normal tissue, is considered an ideal cancer therapy. Although the proposed mechanism of action of antibody therapeutics varies by targets and indications, antibody-dependent cytotoxic...
متن کاملThe 2012 Antibody Special Issue
Through the joint efforts of Protein Engineering Design & Selection and The Antibody Society, this 2012 Antibody Special Issue addresses fundamental issues and advances in our field. Contributions from the participating research groups are timely, creative and thoughtful. They emphasize the sophistication of research that underlies the growing impact of antibody engineering in the development o...
متن کامل